» Articles » PMID: 32722287

Pan-Cancer Analysis of the Genomic Alterations and Mutations of the Matrisome

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Jul 30
PMID 32722287
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The extracellular matrix (ECM) is a master regulator of all cellular functions and a major component of the tumor microenvironment. We previously defined the "matrisome" as the ensemble of genes encoding ECM proteins and proteins modulating ECM structure or function. While compositional and biomechanical changes in the ECM regulate cancer progression, no study has investigated the genomic alterations of matrisome genes in cancers and their consequences. Here, mining The Cancer Genome Atlas (TCGA) data, we found that copy number alterations and mutations are frequent in matrisome genes, even more so than in the rest of the genome. We also found that these alterations are predicted to significantly impact gene expression and protein function. Moreover, we identified matrisome genes whose mutational burden is an independent predictor of survival. We propose that studying genomic alterations of matrisome genes will further our understanding of the roles of this compartment in cancer progression and will lead to the development of innovative therapeutic strategies targeting the ECM.

Citing Articles

Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma.

Kuras M, Betancourt L, Hong R, Szadai L, Rodriguez J, Horvatovich P Cancers (Basel). 2025; 17(5).

PMID: 40075679 PMC: 11899103. DOI: 10.3390/cancers17050832.


Comprehensive analysis of mitochondrial-related gene signature for prognosis, tumor immune microenvironment evaluation, and candidate drug development in colon cancer.

Wu H, Zhang W, Chang J, Wu J, Zhang X, Jia F Sci Rep. 2025; 15(1):6173.

PMID: 39979377 PMC: 11842742. DOI: 10.1038/s41598-024-85035-2.


N-Methylandenosine-related lncRNAs as potential biomarkers for predicting prognosis and the immunotherapy response in pancreatic cancer.

Bai Z, Xia Q, Xu W, Wu Z, He X, Zhang X Cell Mol Life Sci. 2025; 82(1):48.

PMID: 39833465 PMC: 11753445. DOI: 10.1007/s00018-024-05573-w.


Proteomic insights into the extracellular matrix: a focus on proteoforms and their implications in health and disease.

Bains A, Naba A Expert Rev Proteomics. 2024; 21(11):463-481.

PMID: 39512072 PMC: 11602344. DOI: 10.1080/14789450.2024.2427136.


SCGB1A1 as a novel biomarker and promising therapeutic target for the management of HNSCC.

Wang J, Xu Q, Yu J, Xu A, Yu L, Chen Z Oncol Lett. 2024; 28(5):527.

PMID: 39268163 PMC: 11391500. DOI: 10.3892/ol.2024.14660.


References
1.
Mitra S, Tiwari K, Podicheti R, Pandhiri T, Rusch D, Bonetto A . Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression. Cancers (Basel). 2019; 11(10). PMC: 6826756. DOI: 10.3390/cancers11101513. View

2.
Naba A, Clauser K, Hoersch S, Liu H, Carr S, Hynes R . The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics. 2011; 11(4):M111.014647. PMC: 3322572. DOI: 10.1074/mcp.M111.014647. View

3.
Malik R, Lelkes P, Cukierman E . Biomechanical and biochemical remodeling of stromal extracellular matrix in cancer. Trends Biotechnol. 2015; 33(4):230-6. PMC: 4380578. DOI: 10.1016/j.tibtech.2015.01.004. View

4.
Gocheva V, Naba A, Bhutkar A, Guardia T, Miller K, Li C . Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A. 2017; 114(28):E5625-E5634. PMC: 5514763. DOI: 10.1073/pnas.1707054114. View

5.
Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View